|
|
|
|
| LEADER |
00000cam a2200000 a 4500 |
| 001 |
SCIDIR_on1191684855 |
| 003 |
OCoLC |
| 005 |
20231120010507.0 |
| 006 |
m o d |
| 007 |
cr |n||||||||| |
| 008 |
200831s2020 mau o 000 0 eng d |
| 040 |
|
|
|a YDX
|b eng
|e pn
|c YDX
|d OPELS
|d OCLCF
|d EBLCP
|d OCLCQ
|d OCLCO
|d OCLCQ
|d OCLCO
|
| 019 |
|
|
|a 1195467664
|
| 020 |
|
|
|a 9780128210185
|q (electronic bk.)
|
| 020 |
|
|
|a 0128210184
|q (electronic bk.)
|
| 020 |
|
|
|z 9780128210178
|
| 020 |
|
|
|z 0128210176
|
| 035 |
|
|
|a (OCoLC)1191684855
|z (OCoLC)1195467664
|
| 050 |
|
4 |
|a RS400
|
| 082 |
0 |
4 |
|a 615.19
|2 23
|
| 245 |
0 |
0 |
|a Annual reports in medicinal chemistry.
|n Volume 54 /
|c edited by Stephen Neidle.
|
| 260 |
|
|
|a Cambridge, MA :
|b Academic Press,
|c 2020.
|
| 300 |
|
|
|a 1 online resource
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Issn Ser.
|
| 505 |
0 |
|
|a Intro -- Quadruplex Nucleic Acids As Targets For Medicinal Chemistry -- Copyright -- Contents -- Contributors -- Preface -- Foreword -- References -- Part 1: Fundamentals of quadruplexes and their biology -- Chapter One: Fundamentals of G-quadruplex biology -- 1. Introduction -- 2. Experimental approaches to G-quadruplex biology -- 2.1. Some general principles and potential pitfalls -- 2.2. In silico approaches -- 2.3. Antibodies -- 2.4. Chromatin immunoprecipitation -- 2.5. Small molecules -- 2.6. Microscopy -- 2.7. Genetic approaches -- 3. Biological processes impacted by G-quadruplexes
|
| 505 |
8 |
|
|a 3.1. Chromatin -- 3.2. Transcription -- 3.3. Messenger RNAs -- 3.4. Replication and genome stability -- 3.5. Telomeres -- 3.6. Mitochondria -- 3.7. Cancer -- 4. Closing remarks -- Acknowledgments -- References -- Chapter Two: Quadruplex structure and diversity -- 1. Structural elements of G-quadruplexes -- 1.1. G-tetrads -- 1.1.1. Individual component-G-tetrad configuration -- 1.1.2. Relational component-G-tetrad stacking interaction -- 1.1.3. Topological rules -- 1.2. G-columns -- 1.2.1. Individual component-G-column continuity -- 1.2.2. Relational component-G-column relative directionality
|
| 505 |
8 |
|
|a 1.2.3. Topological rules -- 1.3. Loops -- 1.3.1. Individual component-Type of loops -- 1.3.2. Relational component-Peripheral structures -- 1.3.3. Topological rules -- 2. DNA G-quadruplexes -- 2.1. Canonical DNA G-quadruplexes -- 2.1.1. Parallel -- 2.1.2. Hybrid-Form 1 and form 2 -- 2.1.3. Anti-parallel-Chair and basket -- 2.2. Non-canonical DNA G-quadruplexes -- 2.2.1. Discontinuous G-columns -- 2.2.2. Peripheral structures -- 2.2.3. Left-handed G-column progressions -- 3. RNA G-quadruplexes -- 3.1. Canonical RNA G-quadruplex -- 3.2. Non-canonical RNA G-quadruplexes
|
| 505 |
8 |
|
|a 3.2.1. FMRP-binding RNA aptamer -- 3.2.2. Spinach RNA aptamer and its derivatives -- 4. Conclusions -- References -- Part 2: Quadruplex targets in human and other organisms -- Chapter Three: Telomeric quadruplexes as therapeutic targets -- 1. Introduction -- 2. Telomere maintenance mechanisms and cancer -- 3. Structures of telomeric quadruplexes in vitro and in vivo -- 4. Ligand-based targeting of telomeric quadruplexes toward cancer therapy -- 5. Concluding remarks -- Acknowledgments -- References -- Chapter Four: Viral G-quadruplexes: New frontiers in virus pathogenesis and antiviral therapy
|
| 505 |
8 |
|
|a 1. Introduction -- 2. DNA viruses -- 2.1. Herpesviruses -- 2.1.1. Alpha-herpesviruses -- 2.1.2. Beta-herpesviruses -- 2.1.2.1. Human cytomegalovirus -- 2.1.2.2. Human herpesviruses 6A/6B -- 2.1.3. Gamma-herpesviruses -- 2.1.3.1. Epstein-Barr virus -- 2.1.3.2. Kaposi�s sarcoma-associated herpesvirus -- 2.2. Other DNA viruses -- 2.2.1. Human papillomavirus -- 2.2.2. Hepatitis B virus -- 3. RNA viruses -- 3.1. Flaviviruses -- 3.1.1. ZIKA virus -- 3.1.2. Hepatitis C virus -- 3.2. Filoviruses -- 3.3. SARS coronavirus -- 4. Retroviruses -- 4.1. Lentiviruses -- 4.1.1. Human immunodeficiency virus type 1
|
| 650 |
|
0 |
|a Clinical chemistry.
|
| 650 |
|
0 |
|a Pharmaceutical chemistry.
|
| 650 |
|
2 |
|a Chemistry, Clinical
|0 (DNLM)D002624
|
| 650 |
|
2 |
|a Chemistry, Pharmaceutical
|0 (DNLM)D002626
|
| 650 |
|
6 |
|a Chimie clinique.
|0 (CaQQLa)201-0016714
|
| 650 |
|
6 |
|a Chimie pharmaceutique.
|0 (CaQQLa)201-0028674
|
| 650 |
|
7 |
|a Clinical chemistry
|2 fast
|0 (OCoLC)fst00864330
|
| 650 |
|
7 |
|a Pharmaceutical chemistry
|2 fast
|0 (OCoLC)fst01060115
|
| 700 |
1 |
|
|a Neidle, Stephen.
|
| 776 |
0 |
8 |
|i Print version:
|t Annual reports in medicinal chemistry. Volume 54.
|d Cambridge, MA : Academic Press, 2020
|z 0128210176
|z 9780128210178
|w (OCoLC)1139946336
|
| 830 |
|
0 |
|a Issn Ser.
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/bookseries/00657743/54
|z Texto completo
|
